TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
In the phase III SYNCHRONIZE-2 trial, adults with type 2 diabetes and obesity taking investigational survodutide lost more weight and had larger HbA1c reductions than participants taking placebo over 76 weeks. Gastrointestinal side effects led 18% of participants in each drug-dose group to discontinue the trial regimen, leaving tolerability a major concern.
The investigational GIP/GLP-1 drug survodutide reduced weight and HbA1c more than placebo over 76 weeks in adults with type 2 diabetes and obesity, but gastrointestinal side effects led 18% of participants in each dose group to stop the trial regimen. The phase III SYNCHRONIZE-2 results, presented at the European Association for the Study of Diabetes meeting in Milan and published in the New England Journal of Medicine, show both potential metabolic benefits and a tolerability challenge for the drug.
Participants received once-weekly injections of 3.6 mg survodutide, 6 mg survodutide, or placebo. At week 76, average body-weight reductions were 8.2% and 9.8% in the two drug groups, respectively, compared with 3.9% with placebo. At least 5% weight loss occurred in 57.6% and 64.5% of participants taking survodutide, versus 35.1% taking placebo; the reported comparisons with placebo were statistically significant.
Average HbA1c, a measure of blood sugar over time, fell by 0.9 percentage points in the 3.6-mg group and 0.8 points in the 6-mg group. The placebo group’s average reduction was 0.2 points. Baseline mean HbA1c was 7.4%. Sean Wharton of Wharton Medical Clinic Weight and Diabetes Management in Hamilton, Ontario, presented the findings. He said survodutide was associated with improvements in other cardiometabolic measures, including systolic blood pressure, waist circumference and lipids.
Gastrointestinal adverse events were reported by 73% to 78% of participants taking survodutide, compared with 38.6% in the placebo group. Most were described as mild to moderate and temporary. However, adverse events of any kind led 26% in each survodutide group to discontinue treatment, compared with 9% in the placebo group. The report says the drug groups’ gastrointestinal-event discontinuation rate was 18%, versus 1.2% with placebo.
Benefits Meet a Tolerability Test
The results matter because they show that survodutide can improve weight and blood sugar measures in people managing both type 2 diabetes and obesity, while also highlighting that a meaningful share of trial participants could not continue treatment. For patients, clinicians and drug developers, the balance between metabolic benefit and side effects is central to whether a weekly injectable can be used in routine care.
Wharton and colleagues wrote that the weight reduction in the higher-dose group was a magnitude associated with cardiovascular benefits and fewer metabolic and mechanical complications, as well as better quality of life. That is the researchers’ interpretation of the weight-loss level; this trial result alone does not establish that survodutide prevents cardiovascular events or complications. The reported cardiovascular outcomes data are expected from a separate trial.
The findings also should not be read as a direct comparison with other drugs. The source report places survodutide’s results below reported maximum weight-loss and HbA1c reductions for semaglutide, tirzepatide and retatrutide, but those figures come from separate trials. Differences in study populations and methods mean they do not establish how the medicines would compare in a head-to-head test.
Products Worth Considering
Fitbit Versa Smart Watch – Black Aluminum, One Size (S & L Bands Included)
Withings Body Smart Wi-Fi and Bluetooth Body Composition Scale
Philips Sonicare DiamondClean 9900 Prestige Electric Toothbrush
As an affiliate, we earn on qualifying purchases.
How the Trial Was Designed
SYNCHRONIZE-2 was a multinational, double-blind phase III study involving 752 participants: 250 assigned to 3.6 mg, 251 to 6 mg and 251 to placebo. All had type 2 diabetes and a body mass index of at least 27. Their mean age was 55.7 years and mean BMI was 36.5; 49.3% were men. The trial ran from November 2023 through March 2026.
The trial’s population affects how broadly its findings can be applied. It excluded people taking insulin, and most participants had relatively well-controlled blood sugar at the start while using oral glucose-lowering medicines. The report therefore cautions that the results may not represent the wider population of people with diabetes, including those whose condition is treated with insulin.
The researchers also reported lower weight loss in this diabetes trial than the maximum 13% reported in SYNCHRONIZE-1, which excluded participants with diabetes. That earlier study had also flagged tolerability concerns. Differences between the trial populations mean the results should be understood as separate study findings, not a direct comparison of treatment effects.
“Survodutide was associated with improvements in other cardiometabolic parameters, including systolic blood pressure, waist circumference, and lipids.”
— Sean Wharton, MD, presenting the trial findings at the EASD meeting
Who Can Benefit, and at What Cost?
The study does not show whether survodutide reduces heart attacks, strokes or other cardiovascular outcomes; those questions require separate outcome data. The report says results from a cardiovascular outcomes trial are expected later this year, but it does not provide a specific release date.
It is also unclear whether a different dose-escalation approach will reduce nausea or other gastrointestinal effects and lower discontinuation rates. Birkenfeld suggested the escalation schedule may help explain the high dropout rate, but that explanation is not established by the trial results. The source report says the 6-mg dose used a 24-week, six-step escalation and notes Birkenfeld’s view that the schedule had been requested by the FDA.
Finally, the findings do not settle how the drug performs in people using insulin or in a broader range of patients with diabetes. The reported trial population was limited, and comparisons with other medicines are based on separate trials rather than direct testing against survodutide.
Upcoming Titration and Outcomes Data
Boehringer Ingelheim says planned trials will test more flexible, patient-centered dose titration in an effort to improve tolerability. Future results will need to show whether that approach changes gastrointestinal side effects or the proportion of patients who stop treatment.
Another development to watch is the cardiovascular outcomes trial, for which data are expected later this year, according to the source report. Until those results are available, the confirmed evidence from SYNCHRONIZE-2 concerns weight, HbA1c and other reported cardiometabolic measures—not proof of fewer cardiovascular events. Further study will also be needed to clarify how well the findings apply to patients excluded from this trial.
Key Questions
What did SYNCHRONIZE-2 find?
Over 76 weeks, participants taking survodutide lost an average of 8.2% of body weight at 3.6 mg and 9.8% at 6 mg, compared with 3.9% with placebo. Average HbA1c reductions were 0.9 and 0.8 percentage points, versus 0.2 points with placebo.
What was the main tolerability concern?
Gastrointestinal events were more common in the survodutide groups than with placebo. Such events led 18% of participants in each drug group to discontinue the trial regimen, compared with 1.2% in the placebo group.
Does the trial prove survodutide prevents heart disease?
No. The trial reported changes in measures such as blood pressure, waist circumference and lipids, but it did not establish that the drug prevents heart attacks, strokes or other cardiovascular events. Separate outcomes data are expected later this year, according to the report.
Do these findings apply to everyone with type 2 diabetes?
Not necessarily. The trial excluded people taking insulin, and most participants had relatively well-controlled blood sugar while using oral medicines. The findings may not represent the broader diabetes population.
Source: rss
